Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease

Circulation Journal

Volumn 70, Issue 11, 2006, Pages 1451-1456

  Kokubu, Nobuaki ^a   Tsuchihashi, Kazufumi ^a   Yuda, Satoshi ^a   Hase, Mamoru ^a   Eguchi, Mariko ^a   Wakabayashi, Takeru ^a   Hashimoto, Akiyoshi ^a   Nakata, Tomoaki ^a   Miura, Tetsuji ^a   Ura, Nobuyuki ^a   Nagao, Kazuhiko ^b   Tsuzuki, Masahiro ^b   Wakabayashi, Chikashi ^b   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sapporo Gorinbashi Orthopaedic Hospital   (Japan)

Author keywords

Adiponectin; Arteriosclerosis obliterans; Diabetes mellitus; Insulin resistance; Serotonin antagonist

Indexed keywords

ADIPONECTIN; IMMUNOREACTIVE INSULIN; SARPOGRELATE; SEROTONIN 2A ANTAGONIST;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OUTCOME ASSESSMENT;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BLOOD PRESSURE; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SUCCINATES;

EID: 33750544945     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1451     Document Type: Article

References (29)

1. Shimizu Y, Minatoguchi S, Hashimoto K, Uno Y, Arai M, Wang N, et al. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol 2002; 40: 1347-1355.
2. Horibe E, Nishigaki K, Minatoguchi S, Fujiwara H. Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease. Circ J 2004; 68: 68-72.
3. Fujita M, Minamino T, Sanada S, Asanuma H, Hirata A, Ogita H, et al. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. J Mol Cell Cardiol 2004; 37: 1219-1223.
4. Tanaka T, Fujita M, Nakae I, Tamaki S, Hasegawa K, Kihara Y, et al. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol 1998; 32: 1982-1986.
5. Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR, Emanuelsson H, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Circulation 1993; 88: 1588-1601.
6. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
7. Higashiura K, Ura N, Ohata J, Togashi N, Takagi S, Saitoh S, et al. Correlation of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol (Oxf) 2004; 61: 753-759.
8. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, et al. Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 2004; 68: 1194-1198.
9. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285-289.
10. Piot C, Fontbonne A, Sultan A, Rasamiosa M, Mariano-Goulart D, Davy JM, et al. Inflammatory parameters are independent predictors of severe epicardial coronary stenosis in asymptomatic diabetic patients with silent myocardial ischemia. Diabetes Care 2003; 26: 545-546.
11. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
12. Katz MF, Farber HW, Dodds-Stitt Z, Cruikshank WW, Beer DJ. Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. J Leukoc Biol 1994; 55: 567-573.
13. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. Blood Coagul Fibrinolysis 2005; 16: 423-428.
14. Yamakawa J, Takahashi T, Itoh T, Kusaka K, Kawaura K, Wang XQ, et al. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 2003; 26: 2477-2478.
15. Hayashi T, Sumi D, Matsui-Hirai H, Fukatsu A, Arockia Rani P J, Kano H, et al. Sapogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis 2003; 168: 23-31.
16. Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, et al. The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin Exp Pharmacol Physiol 1999; 26: 461-464.
17. Takahashi T, Yano M, Minami J, Haraguchi T, Koga N, Higashi K, et al. Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Res Clin Pract 2002; 58: 123-129.
18. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ 2004; 68: 975-981.
19. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
20. Kaplan NM. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520.
21. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
22. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-59.
23. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
24. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895-906.
25. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponection in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385-392.
26. Takishita E, Takahashi A, Harada N, Yamato M, Yoshizumi M, Nakaya Y. Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. J Cardiovasc Pharmacol 2004; 43: 266-270.
27. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999; 100: 483-489.
28. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43: 533-549.
29. Igarashi M, Okuda T, Oh-I T, Koga M. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. J Dermatol 2000; 27: 643-650.